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Abstract
Background: Brucellosis is a zoonosis that occurs worldwide. The disease has been completely eradicated in
livestock in Sweden in 1994, and all cases of confirmed human brucellosis are imported into Sweden from other
countries. However, due to an increase in the number of refugees and asylum seekers from the middle-east to
Sweden, there is a need to improve the current diagnostic methodology for Brucella melitensis. Whilst culture of
Brucella species can be used as a diagnostic tool, real-time PCR approaches provide a much faster result. The aim of
this study was to set up a species-specific real-time PCR for the detection of all biovars of Brucella melitensis, which
could be used routinely in diagnostic laboratories.
Methods: A Brucella melitensis real-time PCR assay was designed using all available genomes in the public database
of Brucella (N = 96) including all complete genomes of Brucella melitensis (N = 17). The assay was validated with a
collection of 37 Brucella species reference strains, 120 Brucella melitensis human clinical isolates, and 45 clinically
relevant non-Brucella melitensis strains.
Results: In this study we developed a single real-time PCR for the specific detection of all biovars of Brucella melitensis.
Conclusions: This new real-time PCR method shows a high specificity (100%) and a high sensitivity (1.25 GE/μl) and
has been implemented in the laboratories of four governmental authorities across Sweden.
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Background
Despite ongoing eradication programs, brucellosis is a wide-
spread zoonosis that infects mainly cattle, sheep, goats, and
pigs. It also leads to considerable financial losses in animal
husbandry due to abortion and fertility problems in cattle,
sheep and goats [1, 2]. Some Brucella species can also infect
humans and more than 500,000 human cases are reported
annually worldwide [3]. Brucellosis is a febrile illness, some-
times with localized bone and tissue infection, or multi-
organ disease. Transmission to humans occurs through
different routes: the ingestion of unpasteurized milk and
dairy products; direct contact with infected animal tissues;
or accidental ingestion, inhalation or injection of cultured
Brucella [4]. Most human Brucellosis cases occur in Syria,
Turkey, Mexico and Iran, but also around the
Mediterranean basin (Portugal, Spain, Southern France,
Italy, Greece, Turkey, North Africa) [3]. Brucella com-
prises six classical species (B. abortus, B. canis, B. meliten-
sis, B. neotomae, B. ovis, and B. suis) and five novel species
(B. ceti, B. microti, B. inopinata, B. papionis and B. pinni-
pedialis). B. melitensis is recognized as the main human
pathogen associated with human outbreaks worldwide [3,
5, 6]. The species of the genus Brucella can be distin-
guished on the basis of phenotype, genotype and preferred
host. Sweden was officially declared free of brucellosis in
1994 [7] and all human cases in Sweden originate from
countries abroad. The incidence in Sweden is between 1
and 20 reported cases per year according to the Swedish
National Surveillance System SmiNet-2 [8]. The gold
standard method for its diagnosis is the isolation of the bac-
teria from clinical samples via blood cultures and identifica-
tion by classical microbiological tube testing. Brucella
grows slowly and visible cultures appear after 3–4 days, but
it can take more than 2 weeks to obtain a definitive result
[9]. Due to its pathogenicity, a biosafety level 3 laboratory
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(BSL-3) is mandatory when handling Brucella organisms.
Laboratory-acquired infections are rarely diagnosed or
reported, however they do occur [9, 10].
The application of DNA-based methods for Brucella
diagnosis is challenging, since all Brucella species have a
very high degree of genetic homology (up till 99.9%), as
shown by whole genome sequencing of B. abortus, B.
melitensis, and B. suis [11–14]. However, several groups
have recently developed PCR-based assays for the dis-
crimination among species and biovars of Brucella.
Three Brucella species B. abortus, B. melitensis, and B.
suis have been sub-typed into biovars [15, 16]. All spe-
cies within the genus Brucella show an average similarity
of 99% across the entire genome and a range between
93% and 99.9% based on analysis and nonparametric in-
ference (ANI) analysis. Data from all public available
complete genome sequences of all type strains and refer-
ence strains were included in the design of primers and
probes for the real-time PCR assay of this study. One
multiplex PCR (AMOS) developed by Bricker and Halling
in 1994, is applicable to differentiate between B. abortus
biovars 1, 2 and 4, B. melitensis, and B. ovis, B. suis biovar 1
by specific PCR products based on unique chromosomal
loci of the mobile genetic element IS711 in their genome
[17]. This PCR was later improved by another laboratory by
adding specific primers for the identification of B. abortus
biovars 5, 6, 9 and genotype 3b of biovar 3 [18]. In 2009,
Huber et al. developed a random amplified polymorphic
DNA PCR assay to differentiate all recognized Brucella
species, including the marine mammals-infecting species B.
ceti and B. pinnipedialis [19]. However, all published
methods are developed to distinguish species and biovars
mainly by gel-based bar patterns and the majority of de-
scribed methods were tested with a few strains.
Kim et al. [20] developed a new real-time PCR for dis-
tinguishing B. abortus from other Brucella species,
which is based on a single nucleotide polymorphism.
However, there was a need for a reliable real-time PCR
for the detection of B. melitensis at the species level [21].
The method has to be validated for clinical purposes
with a large number of human isolates to fulfill the val-
idation requirements of the certified laboratory of the
public health institute. A Brucella genus specific real-
time PCR assay is currently in use at the Public Health
Agency in Sweden (FOHM). However, B. melitensis is
the most prevalent species, and we need to be able to
differentiate to the species level, due to the epidemio-
logical significance of B. melitensis [21].
Methods
With the aim of developing a real-time PCR assay for
the detection of all known species and biovars of B.
melitensis, the genomes of B. ceti, B. inopinata, B. neoto-
mae and B. suis biovar 4 were sequenced and analyzed.
This as necessary due to the lack of necessary genome
data in the publicly available databases at the start of this
project [14]. The panel to validate the inclusivity and ex-
clusivity of the real-time PCR assay contained all known
biovars of Brucella, as well as 45 other non-Brucella
DNA from American Type Culture Collection (ATCC),
Culture Collection University of Gothenburg (CCUG)
and National Collection of Type Cultures (NCTC) with
clinical relevance. A number of environmental samples,
as well as the closely related species Ochrobactrum
anthropi, were also tested in this study (Tables 1 and 2).
Bacterial strains and growth conditions
A collection of 31 Brucella sp. reference strains (Table 1)
and 120 B. melitensis human clinical isolates were iso-
lated in the BSL-3 laboratory at the FOHM, by cultiva-
tion on 5% sheep blood agar plates in a 5%–10% CO2
atmosphere at 37 °C for 48 h. All non-Brucella strains
were routinely cultivated on 5% sheep blood agar over
night at 37 °C.
The B. melitensis human clinical isolates were col-
lected between 1994 and 2016 from Swedish patients,
who had returned from Brucella-endemic countries, in a
biorepository of the FOHM and used as stipulated in the
regulations for diagnostic development and quality as-
sessment. The FOHM performs all Brucella diagnostics
on human samples in Sweden, and the B. melitensis iso-
lates used in this study have previously been confirmed
by cultivation, a general real-time PCR amplifying DNA
of all Brucella strains, as well as by Matrix Assisted
Laser Desorption/Ionization Time of Flight Mass Spec-
trometry (MALDI-TOF MS) [22, 23]. Ethical review of
research involving humans is not applicable for diagnos-
tic development and quality assessment.
DNA extraction
Bacterial DNA was extracted using the commercially
available EZ1® DNA Tissue Kit from (Qiagen, Stockholm,
Sweden) according to the protocol from the manufacturer
and stored at 4 °C until use. A volume of 5 μl of seal her-
pes virus cell culture was used in each sample of the total
volume of 200 μl in the extraction step as a process con-
trol. Each sample was eluted in 50 μl elution buffer.
Bioinformatic analyses, primer & probe design and
real-time PCR
In order to identify a B. melitensis-specific target(s), all
available genomes in the public database of Brucella
(N = 96) including all complete genomes of B. melitensis
(N = 17) were used in the design of primers and probes.
A 2 basepair deletion which is highly specific for B. meli-
tensis was found in the acetyl-CoA acetyltransferase
gene. Primers were designed flanking this deletion and a
short 12-mer MGB probe was placed over the area with
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the deletion. The forward nucleotide sequence 5′-GC
TCGACACAAAGGGCCA-3′ (Biomers, Germany) and
the reverse nucleotide sequence 5′-CAAGCGTGGTCT
GGCGA-3′ (Biomers, Germany) were used with the FAM-
labelled hydrolysis probe -CCGAGATACAAA-MGB (Ap-
plied Biosystems®).
The real-time PCR assays were carried out in 25 μL
reaction mixtures containing 5 μL template DNA, in
PerfeCta Multiplex qPCR SuperMix (Applied Biosys-
tems®) diluted in UltraPure™ DNase/RNase-Free Distilled
Water (Invitrogen™), 0.9 μM of each primer, and 0.2 μM
probe. Amplification and detection were performed
using two different PCR machines, an ABI-7500/96-well
plates real-time FAST PCR platform, and a StepOne
Plus real-time PCR system (Applied Biosystems®).
Thermocycling parameters were as follows: inactivation
95 °C for 3 min, followed by 45 cycles 95 °C for 3 s, and
annealing at 60 °C for 30 s. The baseline and threshold
were set using the auto-baseline and threshold feature in
StepOneplus Software v2.2.2 (Applied Biosystems®). Sam-
ples were considered positive if target amplification was
detected within 40 cycles.
Determination of the real-time PCR limit of detection
The limit of detection (LOD) was defined by using the
Brucella ATCC 23456 strain with 106, 105, 104, 103, 102,
50, 25, 12.5, 6.25, 3.125, 1.56, 0.78, 0.39 genome equiva-
lents per reaction. LOD samples were analysed in six
replicates for each concentration and with five runs on 5
days (Fig. 1).
Internal amplification control (IAC)
As internal amplification control (IAC), Phocine Herpes-
virus 1 (PhHV-1) aliquots with a known DNA concen-
tration and a target quantification cycle (Cq) of 32 was
used [24].
Results and discussion
Real-time PCR is a rapid and reliable method for the
analysis of Brucella in clinical samples. However, the
high genomic similarity between different Brucella spe-
cies makes the design of a species-specific real-time PCR
assay difficult. An alternative attempt to use a probe
(FAM-CCGCCGAGATACAAA) with Tm 68–70 °C (Pri-
mer Express v 3.0) resulted in a signal for all Brucella
species, but also a signal for non-melitensis species. To
increase the discriminatory effect, a shorter probe
(FAM-CCGAGATACAAA-MGB) with Tm 57 °C was
used. By using this shorter probe we could eliminate all
the non-specific amplification derived from other Bru-
cella species than B. melitensis.
The method was validated according to Broeders et
al. 2014 [25] and according to the validation standards
of the Swedish National Veterinary Institute (SVA), the
Public Health Agency of Sweden (FOHM), the Swedish
National Food Agency (NFA) and the Swedish Defense
Research Agency (FOI). The validation comprised ap-
plicability, practicability, specificity, linearity, and
sensitivity.
Table 1 Reference strains tested to assess the sensitivity of
Brucella melitensis specific real-time PCR assay
Species Biotype Strain






























B. ovis ATCC 25840
NCTC 10512
B. ceti NCTC 12891
B. inopinata CAPM 6436
B. microti CAPM 6434
B. neotomae ATCC 23459
B. pinnipedialis NCTC 12890
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Applicability
No false positive or false negative result is acceptable in
clinical BSL3 pathogen diagnostics. To guarantee a cor-
rect identification of BSL3- pathogens, we strongly rec-
ommend isolation of the bacteria on selective Brucella
agar plates. This enables evaluation of the phenotypic
properties of the strains, such as colony morphology,
and enriches the molecular target of the PCR, as well as
reduces the concentration of potential PCR inhibitors.
Even after the enrichment an internal PCR process con-
trol is recommended as described above. All strains in
our validation were cultured under the same conditions
as bacterial strains were isolated in the clinical diagnos-
tics workflow. The real-time PCR method was therefore
recognized as applicable in combination with the isola-
tion of bacteria from clinical specimens.
Specificity
The assay was tested with 120 human clinical B. meliten-
sis isolates, 31 other non B. melitensis Brucella strains,
45 non B. melitensis strains, and 6 B. melitensis refer-
ence strains. There was no amplification from any other
Brucella species other than B. melitensis. The specificity
of this method was 100% because all 126 B. melitensis
samples were tested positive while all 76 non-B. meliten-
sis samples gave no amplification in the real-time PCR.
Practicability
The assay was used for the identification of Brucella
samples from the first External Quality Assurance Exer-
cises (EQAEs) on highly infectious agents (BSL-3) from
the EU financed project “Efficient response to highly
dangerous and emerging pathogens” (EMERGE). The re-
sults obtained with this assay conformed to the results
of other laboratories.
Sensitivity
The limit of detection was 6.25 genome equivalents of B.
melitensis (ATCC 23456) per reaction of template DNA
(1.25 GE/μl). At a DNA concentration of 3.125 genome
equivalents per reaction, 80% of the reactions were still
positive (Fig. 1).
Linearity
The linear dynamic range of this PCR assay was deter-
mined by testing serially diluted DNA of B. melitensis
Table 2 None Brucella strains used in the study for exclusivity
test
Species Strain
Actinobacillus pleuropneumoniae CCUG 12837
Actinomyces pyogenes CCUG 13230
Alcaligenes denitrificans CCUG 407
Bacillus antracis NCTC1328
Bacillus cereus CCUG 7414
Bacillus subtilis ATCC 6633
Bacteroides fragilis ATCC 25285
Bordetella bronchiseptica CCUG 219
Burkholderia mallei NCTC120
Burkholderia pseudomallei NCTC8707
Clostridium perfringens CCUG 1795
Enterococcus fecalis ATCC 29212
Erysipelotrix rhusiopatiae CCUG 221
Escherichia coli ATCC 35218
Escherichia coli (EHEC) EDL333
Escherichia coli (VTEC) 2954-06
Fusobacterium necrophorum CCUG 9994
Haemophilus influenzae ATCC 49247
Haemophilus somnus CCUG 28029
Klebsiella oxytoca CCUG 15717
Klebsiella pneumoniae CCUG 225
Listeria monocytogenes CCUG 15527
Nocardia asteroides CCUG 10073
Ochrabactrum anthropi ATCC 49188
Pasteurella multocida CCUG 229
Pasteurella pneumotropica CCUG 12398
Proteus mirabilis CCUG 26767
Pseudomonas aeruginosa CCUG 17619
Rhodococcus equi CCUG 892
Salmonella Dublin CCUG 35631
Salmonella Thyphimurium CCUG 31969
Salmonella Zanzibar CCUG 41921
Staphylococcus aureus CCUG 4151
Staphylococcus intermedius CCUG 49053
Streptobacillus moniliformis CCUG 33440
Streptococcus agalactiae CCUG 39325
Streptococcus dysgalactiae CCUG 27436
Streptococcus equi CCUG 27367
Streptococcus pyogenes CCUG 12701
Streptococcus uberis CCUG 27444
Streptococcus zooepidemicus CCUG 23256
Table 2 None Brucella strains used in the study for exclusivity
test (Continued)
Taylorella equigenitalis CCUG 16464
Yersinia enterocolitica CCUG 8239
Yersinia pestis 570-04
Yersinia pseudotuberculosis CCUG 5855
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strain ATCC 23456. The regression coefficient calculated
from the regression line in the standard curve was
R2 = 0.993, y-intercept = 37.766.
In conclusion, the novel real-time PCR assay is highly
sensitive and reliable for the rapid detection of all bio-
vars of B. melitensis. It is an important tool for diagnos-
tic laboratories for clinical samples from both humans
and animals.
Conclusions
This new real-time PCR method for the detection of all
biovars of B. melitensis shows a high specificity (100%)
and a high sensitivity (1.25 GE/μl) and has been success-
fully implemented in laboratories of four governmental au-
thorities across Sweden (National Food Agency, National
Veterinary Institute, Swedish Defence Research Agency
and The Public Health Agency of Sweden).
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